Chong Kun Dang’s innovative new medicine pipeline is headed towards the world.

2013年11月5日 · Having developed Duvie®, the new drug for type II diabetes, Chong Kun Dang is actively expanding its global presence with the best-in-class anti-cancer pipelines (CKD-516 …

We are moving forward to become a global leader in probiotics & pharmaceuticals with world-class technology and continuous and innovative research & development. Chong Kun Dang …

We at CKD OTTO Pharma are not only committed to innovation in cancer treatment, but also to safety and quality. GMP certified, our production site is also set for EMA (European Medicines …

CKD-950. A3 Adenosine receptor agonist (A3AR agonist) License-in from Can-fite Biopharma in Israel; Hepatocellular carcinoma: CKD-951. A3 Adenosine receptor agonist (A3AR agonist) …

ABOUT Company KyongBo Pharmaceuticals, a leading global pharmaceutical company responsible for human health. CKD Holdings was established in November of 2013 when …

CKD BiO plans to expand its growth as a leading global company by high quality medicine supplies and probiotics production, continuous exports, and focused efforts on micro-biome …

2023年11月6日 · CKD Pharm has completed a European phase 1 clinical trial of CKD-510 for treating Charcot-Marie-Tooth (CMT), a rare disease caused by a genetic abnormality. In …

At CKD OTTO Pharma, we take pride in our role as a dynamic global business that unites people and markets worldwide. With commitment to innovation, excellence and customer satisfaction, …

2023年2月6日 · The agreement provides CKD a license for global, target-specific rights to Synaffix’s proprietary ADC technology, adding a new ADC drug candidate to CKD’s pipeline. …